comparemela.com

Latest Breaking News On - Agreement development of sales - Page 1 : comparemela.com

Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplements in Brazil

Evolva Holding SA / Key word(s): Agreement/Development of Sales Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplements in Brazil 12-May-2022 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the conte.

Adhoc: Evolva Holding SA: Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplements in Brazil

Evolva Holding SA / Key word(s): Agreement/Development of Sales Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplements in Brazil 12-May-2022 / 07:01 CET/CEST Release

DGAP-News: SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India

DGAP-News: SphingoTec GmbH / Key word(s): Agreement/Development of Sales SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India 17.03.2022 / 10:00 The issuer is solely responsible for the content of this announcement. The collaboration focuses o.

DGAP-News: SphingoTec GmbH: SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India

DGAP-News: SphingoTec GmbH / Key word(s): Agreement/Development of Sales SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India 17.03.2022

EQS-Adhoc: Lonza Group AG: Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply

EQS-Adhoc: Lonza Group AG: Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply 16-Jul-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza s Ibex

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.